Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 29

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 29
---
    non-cash stock-based compensation 
     (855) 
     (1,179) 
     (2,899) 
     (3,699)
  
    Operating
    costs and expenses excluding non-cash stock-based compensation 
    $1,581  
    $2,413  
    $5,926  
    $6,969 

    Operating
    costs and expenses excluding non-cash stock-based compensation: 

    Cancer
    Vaccines 
    $884  
    $1,614  
    $3,714  
    $3,988 
  
    CAR-T
    Therapeutics 
     689  
     789  
     2,180  
     2,943 
  
    Other 
     8  
     10  
     32  
     38 
  
    Total 
    $1,581  
    $2,413  
    $5,926  
    $6,969 
  
    Operating costs and expenses excluding non-cash stock-based compensation 
    $1,581  
    $2,413  
    $5,926  
    $6,969 

    July
    31,  2025  
    October
    31,  2024 
  
    Total
    assets: 

    Cancer
    Vaccines 
    $9,842  
    $12,917 
  
    CAR-T
    Therapeutics 
     7,691  
     8,535 
  
    Other 
     118  
     139 
  
    Total 
    $17,651  
    $21,591 
  
    Total assets 
    $17,651  
    $21,591 

Operating
costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing
the enterprise.

16

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Information
included in this Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations